Sumary of New digital health technologies could lead to better care for Parkinson’s disease:
- The use of digital health technologies across health care and drug development has accelerated.
- This perspective paper is co-authored by the academic leader of the largest funded project for digital technologies in Europe, Professor Lynn Rochester, University of Newcastle;
- Global collaborative efforts are underway with the goal of advancing the use of digital health technologies for use in Parkinson’s clinical research and therapeutic trials — yet several gaps and barriers stand in the way of success.
- CPP’s Digital Drug Development Tool team at Critical Path Institute consists of industry members, scientific academic advisors, patient research organizations and people living with Parkinson’s all collaborating across the globe to seek advice early and often from regulatory agencies.
- Companies advancing innovative therapies for the treatment of Parkinson’s see the promise of digital technologies, yet they also recognize that there are gaps that are too challenging to overcome on their own.
- CPP’s focus on the voice of people living with Parkinson’s aligns with the U.S. Food and Drug Administration (FDA) and EMA’s vision for patient-focused drug development.
- Related Stories”We felt it was imperative to come together on this paper, at this moment, to bring attention to how existing digital health technologies can complement traditional modalities and transform and accelerate clinical research and therapeutic development,” said Rochester.
- From the direction of research to identifying the tools that can estimate relevant outcome measures in the search for new therapeutics that are directed towards disease modification or improved quality of life, patient input is absolutely integral to its success.